October 1, 2018 (Vol. 38, No. 17)

Bio-Rad Laboratories

Introducing a range of anti-idiotypic antibodies targeting the immune checkpoint inhibitor drugs pembrolizumab and nivolumab. Anti-pembrolizumab and anti-nivolumab antibodies are designed for use in bioanalytical assays to monitor the drug levels in cancer patients. These anti-pembrolizumab and anti-nivolumab antibodies inhibit the binding of the drugs to their target, PD-1, enabling the free drug to be detected. Anti-idiotypic antibodies are generated using the human combinatorial antibody library or HuCAL® and CysDisplay®, a proprietary method of phage display with guided selection methods to obtain highly targeted reagents. These antibodies are approved for in vitro research purposes and for commercial applications of in vitro testing services to support preclinical and clinical drug development and patient monitoring.

Previous articleChronic Back Pain Linked to Three Genetic Variants
Next articleNovel Method Improves Imaging and Progression of Atherosclerotic Plaque